Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma

Frix, Anne-Noëlle; Schleich, Florence; PAULUS, Virginie; GUISSARD, Françoise; HENKET, Monique; Louis, Renaud

doi:10.1016/j.bcp.2020.113944

Article (Scientific journals)

Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma

Frix, Anne-Noëlle; Schleich, Florence; PAULUS, Virginie et al.

2020 • In Biochemical Pharmacology, 179

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/257092

DOI
10.1016/j.bcp.2020.113944

PubMed
32240649

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

FRIX 2020_Effectiveness of omalizumab_Bioch Pharmacol_ppediteur.pdf

Publisher postprint (1.06 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Inflammatory markers; Omalizumab; Predicting factors; Real life effectiveness; Severe asthma

Abstract :

[en] Background: Omalizumab arose as a therapeutic option in patients suffering from moderate to severe refractory allergic asthma. It acts as a humanized monoclonal antibody neutralizing circulating IgE antibodies. Randomized clinical trials and real life clinical studies have already confirmed benefits, cost-effectiveness and applicability of the medication. Method: Our study retrospectively reports on the clinical outcomes and airway inflammation in 157 severe allergic asthmatics who were initiated with omalizumab between 2007 and 2019. Results: After 4 months of therapy, 76% of the patients were judged to have benefited from omalizumab and were admitted to prolonged treatment. During follow-up, we observed an improvement in asthma control, quality of life and spirometric performance. There was also a sustained reduction in exacerbation rate over the years. As for T2 biomarkers, FeNO significantly decreased and, in a subgroup of patients who had repeated sputum inductions, there was also significant reduction in sputum eosinophils but no change in blood eosinophil count. Lastly, we found a correlation between high FeNO levels at baseline and reduction in ACQ scores at 1 year. Conclusion: We conclude that omalizumab shows effectiveness in severe allergic asthma in a real life setting, by reducing exacerbation rate, improving patient perspective outcomes and airway calibre, together with reducing type-2 airway inflammation. © 2020 Elsevier Inc.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Frix, Anne-Noëlle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Schleich, Florence ; Université de Liège - ULiège > Département des sciences de la motricité > Département des sciences de la motricité

PAULUS, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme

GUISSARD, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme

HENKET, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Language :

English

Title :

Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma

Publication date :

2020

Journal title :

Biochemical Pharmacology

ISSN :

0006-2952

eISSN :

1873-2968

Publisher :

Elsevier Inc.

Volume :

179

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

NovartisGlaxoSmithKline Australia, GSK

Available on ORBi :

since 19 February 2021

Statistics

Number of views

55 (4 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Global Initiative for Asthma, Global Strategy for Asthma management and Prevention 2019 [Internet]. [cited 1 dec 2019]. Disponible sur:, 2019 http://www.ginasthma.org/.
ASTHMA FACTS – CDC's National Asthma Control Program Grantees, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, 2013.
Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43:2 (2014), 343–373.
Licari, A., Marseglia, G., Castagnoli, R., Marseglia, A., Ciprandi, G., The discovery and development of omalizumab for the treatment of asthma. Expert Opin. Drug Discov. 10:9 (2015), 1033–1042.
Storms, W., Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy. Am. J. Respir. Med. 1:5 (Oct 2002), 361–368.
D'Amato, G., Stanziola, A., Sanduzzi, A., Liccardi, G., Salzillo, A., Vitale, C., et al. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. [cited 1 dec 2019];9(1). Available on: Multidiscip. Respir. Med. [Internet], 2014 https://mrmjournal.biomedcentral.com/articles/10.1186/2049-6958-9-23.
Holgate, S.T., Chuchalin, A.G., Hébert, J., Lötvall, J., Persson, G.B., Chung, K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allerg. J. Br. Soc. Allerg. Clin. Immunol. 34:4 (Apr 2004), 632–638.
Hanania, N.A., Alpan, O., Hamilos, D.L., Condemi, J.J., Reyes-Rivera, I., Zhu, J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 154:9 (2011), 573–582.
Corren, J., Casale, T.B., Lanier, B., Buhl, R., Holgate, S., Jimenez, P., Safety and tolerability of omalizumab. Clin. Exp. Allerg. 39:6 (2009), 788–797.
Barnes, N., Menzies-Gow, A., Mansur, A.H., Spencer, D., Percival, F., Radwan, A., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J. Asthma 50:5 (2013), 529–536.
Brusselle, G., Michils, A., Louis, R., Dupont, L., Van, B., de, Maele, Delobbe, A., et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir. Med. 103:11 (2009), 1633–1642.
Rubin, A.S., Souza-Machado, A., Andradre-Lima, M., Ferreira, F., Honda, A., Matozo, T.M., et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J. Asthma 49:3 (2012), 288–293.
Korn, S., Thielen, A., Seyfried, S., Taube, C., Kornmann, O., Buhl, R., Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir. Med. 103:11 (2009), 1725–1731.
Molimard, M., Buhl, R., Niven, R., Le Gros, V., Thielen, A., Thirlwell, J., et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir. Med. 104:9 (2010), 1381–1385.
Braunstahl, G.-J., Chen, C.-W., Maykut, R., Georgiou, P., Peachey, G., Bruce, J., The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir. Med. 107:8 (2013), 1141–1151.
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:3 (2005), 309–316.
Cazzola, M., Camiciottoli, G., Bonavia, M., Gulotta, C., Ravazzi, A., Alessandrini, A., et al. Italian real-life experience of omalizumab. Respir. Med. 104:10 (2010), 1410–1416.
Bhutani, M., Yang, W.H., Hébert, J., de Takacsy, F., Stril, J.-L., The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. Fehrenbach H, éditeur. PLoS One, 12(8), 2017, e0183869.
Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360:10 (2009), 973–984.
Cruse, G., Activation of human lung mast cells by monomeric immunoglobulin E. Eur. Respir. J. 25:5 (2005), 858–863.
Djukanović, R., Wilson, S.J., Kraft, M., Jarjour, N.N., Steel, M., Chung, K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 170:6 (2004), 583–593.
Acer, E., Kaya, H., Erdogan, Yüksel Çanakçı, N., Saracoglu, Z.N., The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutaneous Ocular Toxicol. 38:1 (2019), 5–8.
Çildağ, S., Şentürk, T., The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. Adv. Dermatol. Allergol. 35:5 (2018), 516–519.
Yalcin, A.D., Celik, B., Yalcin, A.N., Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol. Immunotoxicol. 38:3 (2016), 253–256.
Hanania, N.A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D.F., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 187:8 (Apr 2013), 804–811.
Humbert, M., Taillé, C., Mala, L., Le Gros, V., Just, J., Molimard, M., Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur. Respir. J., 51(5), 2018, 1702523.
Kallieri, M., Papaioannou, A.I., Papathanasiou, E., Ntontsi, P., Papiris, S., Loukides, S., Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgrad. Med. 129:6 (2017), 598–604.
Demarche, S.F., Schleich, F.N., Henket, M.A., Paulus, V.A., Van Hees, T.J., Louis, R.E., Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre. BMJ Open, 7(11), 2017, e018186.
Verhamme, K.M.C., Lucet, C., Van Meerhaeghe, A., Brusselle, G.G.O., Lambert, M.-L., Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. ERJ Open Res. 5:4 (2019), 00253–2018.